Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan-Reference-Cited by-同舟云学术

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan

Published:2023-12-10 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Hagino Teppei¹^ORCID,Yoshida Mai²,Hamada Risa²,Saeki Hidehisa²^ORCID,Fujimoto Eita³,Kanda Naoko¹^ORCID

Affiliation:

1. Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan

2. Department of Dermatology, Nippon Medical School, Tokyo, Japan

3. Department of Dermatology, Fujimoto Dermatology Clinic, Funabash, Japan

Funder

Initiative for Realizing Diversity in the Research Environment

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2276043

Reference42 articles.

1. Guidelines of care for the management of atopic dermatitis

2. The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society

3. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

4. Atopic dermatitis

5. Targeting the Janus Kinase Family in Autoimmune Skin Diseases

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study;Journal of Dermatological Treatment;2024-04-23

2. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan;Clinical Drug Investigation;2024-03-06

3. A Comprehensive Analysis of Immunoglobulin E Levels, Allergen-Specific Sensitivities, and Clinical Manifestations in Allergic Dermatological Conditions: A Multicenter Retrospective Study in China;Clinical, Cosmetic and Investigational Dermatology;2024-03

4. Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis;Journal of Dermatological Treatment;2024-01-31

5. The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis;Dermatologic Therapy;2024-01